Betamethasone (as dipropionate)

2 Drugs classified under this active ingredient

Corticosteroid, Vitamin D Analog. Calcipotriol 50 mcg/g, Betamethasone (as dipropionate) 0.5 mg/g.
Oint:30/60/120 g. Apply to affected area once daily. The recomm. tmt. period is 4 wks. There is experience with repeated courses up to 52 w ks. If it is necessary to cont. or restart tmt. after 4 wks., tmt. should be cont. after med. review and under regular med. supervis.
When using calcipotriol contain. med. products, the max. dly. dose should not exceed 15 g. The body surface area treated with calcipotriol contain. drugs  should not exceed 30% . See lit.
Topical treatment of stable plaque

psoriasis vulgaris amenable to topical

therapy. For renal /hepatic impair. and  ped. pop. see lit.
C/I: Hypersens. Pts with  erythrodermic, exfoliative and pustular psoriasis.
Pts. with  known disorders of calcium metabolism .
Pts. with viral (e.g. herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis, perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wounds.

Corticosteroid, Vitamin D Analogue. Betamethasone (as dipropionate) 0.5 mg/g, Calcipotriol (as monohydrate) 50 mcg/g.
ALUMINIUM CAN:60 g.
Enstilar foam should be applied to the affected area once dly. The recom. tmt. period is 4 wks. The dly. max. dose should not exceed 15 g, i.e. one 60 g can should last for at least 4 d. 15 g corresponds to the amount admin. from the can if the actuator is fully depressed for approx. one minute. A two-second application delivers approx. 0.5 g. As a guide, 0.5 g of foam should cover an area of skin roughly correspond. to the surface area of an adult hand. Concomit. use with other topic. products contain. calcipotriol in addition to Enstilar: the total dose of all calcipotriol contain. products should not exceed 15 g/d. The total bdy. surf. area treated should not exceed 30%.
Ren. / hep. impair. The safety and efficacy in pts. with severe renal insuffic. or severe Hep. disord. have not been evaluated.
Ped. population:The safety and efficacy in child. below 18 yrs. have not been establish. Enstilar is not indic. for child<18 yrs. of age.
Topical tmt. of psoriasis vulgaris in adults.
C/I: Hypersens.
Pts. with  erythrodermic and pustular psorias.
Pts. with known calcium metabolism disord.